218 related articles for article (PubMed ID: 25968633)
1. Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.
Jin SE; Jin HE; Hong SS
Expert Opin Ther Targets; 2015; 19(10):1319-37. PubMed ID: 25968633
[TBL] [Abstract][Full Text] [Related]
2. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T
Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667
[TBL] [Abstract][Full Text] [Related]
3. L-type amino acid transporter 1 (LAT1): a new therapeutic target for canine mammary gland tumour.
Fukumoto S; Hanazono K; Komatsu T; Ueno H; Kadosawa T; Iwano H; Uchide T
Vet J; 2013 Oct; 198(1):164-9. PubMed ID: 23896327
[TBL] [Abstract][Full Text] [Related]
4. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
Puris E; Gynther M; Huttunen J; Petsalo A; Huttunen KM
J Control Release; 2017 Sep; 261():93-104. PubMed ID: 28662899
[TBL] [Abstract][Full Text] [Related]
5. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors.
Fan X; Ross DD; Arakawa H; Ganapathy V; Tamai I; Nakanishi T
Biochem Pharmacol; 2010 Sep; 80(6):811-8. PubMed ID: 20510678
[TBL] [Abstract][Full Text] [Related]
6. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB
Wang Z; Chi D; Wu X; Wang Y; Lin X; Xu Z; Liu H; Sun J; He Z; Wang Y
J Control Release; 2019 Dec; 316():22-33. PubMed ID: 31676386
[TBL] [Abstract][Full Text] [Related]
8. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
Kanai Y
Pharmacol Ther; 2022 Feb; 230():107964. PubMed ID: 34390745
[TBL] [Abstract][Full Text] [Related]
9. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
Rautio J; Kärkkäinen J; Huttunen KM; Gynther M
Eur J Pharm Sci; 2015 Jan; 66():36-40. PubMed ID: 25305508
[TBL] [Abstract][Full Text] [Related]
10. L-Type amino acid transporter 1 as a target for drug delivery.
Puris E; Gynther M; Auriola S; Huttunen KM
Pharm Res; 2020 May; 37(5):88. PubMed ID: 32377929
[TBL] [Abstract][Full Text] [Related]
11. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
12. [Drug Discovery Targeting an Amino Acid Transporter for Diagnosis and Therapy].
Wiriyasermkul P; Moriyama S; Kongpracha P; Nagamori S
Yakugaku Zasshi; 2021; 141(4):501-510. PubMed ID: 33790117
[TBL] [Abstract][Full Text] [Related]
13. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
Ylikangas H; Malmioja K; Peura L; Gynther M; Nwachukwu EO; Leppänen J; Laine K; Rautio J; Lahtela-Kakkonen M; Huttunen KM; Poso A
ChemMedChem; 2014 Dec; 9(12):2699-707. PubMed ID: 25205473
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.
Shimizu A; Kaira K; Kato M; Yasuda M; Takahashi A; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Asao T; Ishikawa O
Melanoma Res; 2015 Oct; 25(5):399-405. PubMed ID: 26237765
[TBL] [Abstract][Full Text] [Related]
15. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
Huttunen J; Peltokangas S; Gynther M; Natunen T; Hiltunen M; Auriola S; Ruponen M; Vellonen KS; Huttunen KM
Sci Rep; 2019 Sep; 9(1):12860. PubMed ID: 31492955
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor highly-expressed LAT1 transporter with amino acid-modified nanoparticles: Toward a novel active targeting strategy in breast cancer therapy.
Li L; Di X; Wu M; Sun Z; Zhong L; Wang Y; Fu Q; Kan Q; Sun J; He Z
Nanomedicine; 2017 Apr; 13(3):987-998. PubMed ID: 27890657
[TBL] [Abstract][Full Text] [Related]
17. Large neutral amino acid transporter enables brain drug delivery via prodrugs.
Gynther M; Laine K; Ropponen J; Leppänen J; Mannila A; Nevalainen T; Savolainen J; Järvinen T; Rautio J
J Med Chem; 2008 Feb; 51(4):932-6. PubMed ID: 18217702
[TBL] [Abstract][Full Text] [Related]
18. L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors.
Huttunen KM; Huttunen J; Aufderhaar I; Gynther M; Denny WA; Spicer JA
Int J Pharm; 2016 Feb; 498(1-2):205-16. PubMed ID: 26705152
[TBL] [Abstract][Full Text] [Related]
19. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions.
Ichinoe M; Mikami T; Yoshida T; Igawa I; Tsuruta T; Nakada N; Anzai N; Suzuki Y; Endou H; Okayasu I
Pathol Int; 2011 May; 61(5):281-9. PubMed ID: 21501294
[TBL] [Abstract][Full Text] [Related]
20. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
Huttunen J; Gynther M; Vellonen KS; Huttunen KM
Int J Pharm; 2019 Nov; 571():118714. PubMed ID: 31610281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
